Page 27 - Immunization Practices News Today

Nirsevimab, a monoclonal antibody used to protect infants from respiratory syncytial virus (RSV), is in limited supply, according to a CDC announcement.

A flu vaccine that does not require an injection could soon be approved for at-home use following an FDA review.

A flu vaccine that does not require an injection could soon be approved for at-home use following an FDA review.

A flu vaccine that does not require an injection could soon be approved for at-home use following an FDA review.

A flu vaccine that does not require an injection could soon be approved for at-home use following an FDA review.

FDA has approved Penbraya™ (meningococcal groups A, B, C, W and Y vaccine) for active immunization in individuals 10 through 25 years of age.

The single shot will cover the five most common serogroups that cause meningococcal disease in children and young adults.

Medicare open enrollment season started Oct. 15 and ends Dec. 7, and this year there will be more plan choices, more benefit offerings, and potentially some cost savings on medications. There also will be more reason to scrutinize your existing plans and weigh your options. During open enrollment, you can make changes such as join, switch, or drop a private insurer’s Medicare Advantage plan ...

PENBRAYA™ provides the broadest serogroup coverage of any meningococcal vaccine available in the U.S. and has the potential to help simplify complex vaccination schedule in the U.S. The...

By Stephen Nakrosis Pfizer said the Food and Drug Administration approved Penbraya, a vaccine preventing the five most common serogroups causing...